GEN Exclusives

More »

GEN Poll

More »
Apr 09, 2014

Takeda/Lilly’s $9B Actos Verdict

A Louisiana jury this week awarded a staggering $9 billion in punitive damages to the companies behind Actos (Pioglitazone HCl). Takeda Pharmaceutical and its partner from 1999–2006, Eli Lilly, have promised to appeal the decision, which came after the jury decided in favor of plaintiff Terrence Allen of Attica, N.Y., who blamed Actos for causing his bladder cancer after taking the drug for five years. The jury’s decision came in part after hearing that Takeda lost or destroyed documents compiled by 46 current and former employees and sales representatives involved in marketing Actos.

How confident are you that Takeda and Lilly will see the punitive damages reduced substantially on appeal?

A great deal
Not at all

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Sustainability in New Dietary Guidelines

Do you think that sustainability considerations should be incorporated into the new Dietary Guidelines for Americans?

More »